Summit Therapeutics Files 8-K: Financials & Exhibits
Ticker: SMMT · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, exhibits
TL;DR
Summit Therapeutics filed an 8-K, mostly just financials and exhibits. No big news.
AI Summary
On March 22, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida.
Why It Matters
This filing indicates routine financial reporting and exhibit submission, suggesting no immediate major corporate events are being disclosed at this time.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant negative events.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- March 22, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Miami, FL (location) — Address of Principal Executive Offices
- 601 Brickell Key Drive, Suite 1000 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 22, 2024.
In which state is Summit Therapeutics Inc. incorporated?
Summit Therapeutics Inc. is incorporated in Delaware.
What is the address of Summit Therapeutics Inc.'s principal executive offices?
The address of Summit Therapeutics Inc.'s principal executive offices is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
Does this filing report any specific material events?
Based on the provided text, this filing primarily concerns financial statements and exhibits and does not detail specific material events.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-22 08:07:13
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240322.htm (8-K) — 30KB
- a2024_prx0322xelccposter.htm (EX-99.1) — 19KB
- elccposters.htm (EX-99.2) — 23KB
- a2024_prx0322xelccposter001.jpg (GRAPHIC) — 233KB
- a2024_prx0322xelccposter002.jpg (GRAPHIC) — 211KB
- a2024_prx0322xelccposter003.jpg (GRAPHIC) — 217KB
- a2024_prx0322xelccposter004.jpg (GRAPHIC) — 184KB
- a2024_prx0322xelccposter005.jpg (GRAPHIC) — 178KB
- a2024_prx0322xelccposter006.jpg (GRAPHIC) — 88KB
- elccposters001.jpg (GRAPHIC) — 194KB
- elccposters002.jpg (GRAPHIC) — 184KB
- 0001599298-24-000043.txt ( ) — 2294KB
- smmt-20240322.xsd (EX-101.SCH) — 2KB
- smmt-20240322_def.xml (EX-101.DEF) — 14KB
- smmt-20240322_lab.xml (EX-101.LAB) — 25KB
- smmt-20240322_pre.xml (EX-101.PRE) — 15KB
- smmt-20240322_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On March 22, 2024, Summit Therapeutics Inc. (the "Company") issued a press release announcing data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central European Time. The posters will also be made available on the Company's website after the presentation period. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the two posters is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 22, 2024 99.2 Posters 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: March 22, 2024 By: /s/ Ankur Dhingra Chief Financial Officer (Principal Financial Officer)